Abliva Dividends and Buybacks

Dividend criteria checks 0/6

Abliva does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-16.3%

Buyback Yield

Total Shareholder Yield	-16.3%
Future Dividend Yield	0%
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ABLI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABLI's dividend payments have been increasing.

Dividend Yield vs Market

Abliva Dividend Yield vs Market

How does ABLI dividend yield compare to the market?
Segment	Dividend Yield
Company (ABLI)	n/a
Market Bottom 25% (SE)	1.6%
Market Top 25% (SE)	4.6%
Industry Average (Biotechs)	1.5%
Analyst forecast (ABLI) (up to 3 years)	0%

Notable Dividend: Unable to evaluate ABLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABLI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ABLI's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ABLI has not reported any payouts.

Abliva Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

New major risk - Shareholder dilution

New major risk - Financial position

Abliva AB (publ) Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease

Abliva AB (Publ) Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease

New minor risk - Shareholder dilution

Abliva AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 46.093054 million.

Full year 2023 earnings released: kr0.09 loss per share (vs kr0.12 loss in FY 2022)

New minor risk - Share price stability

Abliva (STO:ABLI) Is In A Strong Position To Grow Its Business

Abliva AB (publ) to Report Nine Months, 2024 Results on Nov 21, 2024

Abliva AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

Abliva AB (publ) Achieves Important Milestone in the Ongoing FALCON Study

Abliva AB (publ), Annual General Meeting, May 23, 2024

Here's Why We're A Bit Worried About Abliva's (STO:ABLI) Cash Burn Situation

Chairman of the Board recently bought kr494k worth of stock

Abliva AB (Publ) Announces First Patient Dosed in the Falcon Study

Abliva AB (Publ) Announces Resignation of Edwin Moses as Director

Abliva AB Initiates the Global Falcon Study with Lead Candidate KL1333

No independent directors

Abliva AB (publ), Annual General Meeting, Apr 27, 2023

Abliva AB (publ) to Report First Half, 2023 Results on Aug 18, 2023

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Director recently bought kr35m worth of stock

Abliva AB (publ) to Report Fiscal Year 2022 Results on Feb 24, 2023

No independent directors

Abliva AB (publ) to Report Fiscal Year 2021 Results on Apr 29, 2022

Abliva AB (publ) to Report Fiscal Year 2021 Results on Apr 29, 2022

Full year 2021 earnings: EPS misses analyst expectations

US Food and Drug Administration Approves Abliva's Investigational New Drug (IND) Application for KL1333

Third quarter 2021 earnings released: kr0.086 loss per share (vs kr0.03 loss in 3Q 2020)

We're Keeping An Eye On Abliva's (STO:ABLI) Cash Burn Rate

Abliva Reports Positive Clinical Phase 1A/B Results for KL1333 Including Signs of Efficacy in PMD Patients

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Abliva Completes Phase Ia/Ib Study with KL1333

Full year 2020 earnings released: kr0.24 loss per share (vs kr0.45 loss in FY 2019)

Revenue and earnings miss expectations

New 90-day low: kr0.74

Chief Executive Officer Erik Kinnmann has left the company

Abliva Announces CEO Changes, with Effect from February 3rd

New 90-day low: kr0.77

How Much Is Abliva AB (publ) (STO:ABLI) Paying Its CEO?

Third quarter 2020 earnings released: kr0.03 loss per share

Abliva AB (publ) to Report Fiscal Year 2021 Results on Feb 22, 2022

New 90-day low: kr0.78

New 90-day low: kr0.91

Abliva AB Announces Resignation of Magnus Persson From Board of Directors

Earnings released

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies